Minerva Neurosciences - NERV Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares.
View NERV analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year price targets for Minerva Neurosciences' stock. Their NERV share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 167.6% from the stock's current price.
View analysts price targets for NERV or view top-rated stocks among Wall Street analysts.

Minerva Neurosciences' stock was trading at $6.4080 at the beginning of the year. Since then, NERV shares have decreased by 53.3% and is now trading at $2.99.
View the best growth stocks for 2022 here.

Minerva Neurosciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 249,200 shares, an increase of 79.3% from the October 31st total of 139,000 shares. Based on an average daily volume of 3,610,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 5.5% of the company's shares are sold short.
View Minerva Neurosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our NERV earnings forecast.

Minerva Neurosciences, Inc. (NASDAQ:NERV) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($1.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.76). During the same period last year, the firm posted ($1.52) EPS.

Minerva Neurosciences shares reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.06%), Renaissance Technologies LLC (1.91%), BlackRock Inc. (1.46%), Group One Trading L.P. (0.00%), Point72 Asset Management L.P. (0.47%) and Truist Financial Corp (0.21%). Insiders that own company stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer.
View institutional ownership trends.

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NERV stock can currently be purchased for approximately $2.99.

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $15.97 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($8.76) on an earnings per share basis.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.